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Received February 22, 2012; accepted July 13, 2012AbstractSarcomatous change in hepatocellular carcinoma (HCC) is an uncommon histologic variant of HCC, characterized by the proliferation of
spindle cells or bizarre giant cells. Poor outcome has been reported in most cases after diagnosis. Here, we report the first case of a sarcomatous
HCC with complete central necrosis and rupture of the liver capsule. The patient received target therapy with sorafenib, but died of progressive
intra-abdominal carcinomatosis 3 months after treatment. We reviewed the published reports of 13 patients with sarcomatous HCC that included
computed tomography features and found that our patient was the only one to have received sorafenib. It appears that this patient’s life span was
not significantly prolonged with the use of sorafenib.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Sarcomatous hepatocellular carcinoma (HCC) is an un-
common form of primary liver tumor. The incidence of
sarcomatous HCC has been reported to be 3.9e9.4% in pa-
tients with primary liver cancer.1 The pathogenesis of sarco-
matous HCC remains unknown. Kakizoe and colleagues2
reported that the sarcomatous component of HCC is derived
from a dedifferentiation of anaplastic changes in ordinal HCC
rather than from collided double cancer. Kojiro et al3 reported
that the incidence of sarcomatous HCC was higher in patients
who had received transarterial embolization or hepatic arterialConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Assinfusion. They also observed that the serum alpha-fetoprotein
(AFP) level was greater in patients with ordinary HCC than in
those with sarcomatous HCC. Sarcomatous HCC is known to
be associated with central necrosis and hemorrhage more
frequently than ordinary HCC, because the sarcomatous
component consists of poorly differentiated cells that grow
rapidly, with the neovasculature unable to supply the fast-
growing malignant cells adequately, resulting in central ne-
crosis.4 In this report, we present a case of ruptured sarco-
matous HCC, which manifested atypical computed
tomography (CT) features. Early recognition of sarcomatous
HCC appears important, and surgical intervention to resect the
tumor is indicated for patients with this unfavorable variant.
2. Case report
A 49-year-old man presented with epigastric pain that had
persisted for 5 months and weight loss of 5 kg in 2 months. A
physical examination revealed epigastric tenderness. Laboratoryociation. All rights reserved.
Fig. 1. Abdominal sonography showing a 5.9  3.9 cm heterogeneous mass in
segments 5e7 of the liver.
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aminotransferase, 103 IU/L (normal range: 5e34 IU/L); alanine
aminotransferase, 57 IU/L (normal range: 7e55 IU/L); total
bilirubin, 0.5 mg/dL (normal range: 0.2e1.2 mg/dL); AFP,
1270 ng/mL (normal: <10 ng/mL); and carcinoembryonic anti-
gen, 1.62 ng/mL (normal:<5 ng/mL). Hepatitis C antibody was
negative, but hepatitis B virus surface antigen was positive.
Abdominal ultrasonography revealed a heterogeneous tumor,
5.9 3.9 cm in size, in the right lobe of the liver (Fig. 1). The CT
of the abdomen revealed a cirrhotic appearance of the liver with a
cystic hepatic mass measuring 9.0  9.5  9.3 cm in segments
5e7. The mass had caused liver rupture and outside extension toFig. 2. Computed tomography (CT) of the abdomen revealing a cirrhotic appearance
arrows) in segments 5e7. (A) Noncontrast and dynamic CT; (B) arterial; (C) porta
enhancement or early washout. The portal vein was patent, and no peripheral bilethe adjacent peritoneum (Fig. 2, white arrows). The hepatic mass
had a complete cystic appearance and did not show evidence of
contrast enhancement or early washout during dynamic CT scan
(Fig. 2AeD). There was no enhancing soft-tissue component
within the mass. The portal vein was patent. Accordingly, the CT
features of this hepatic mass were not typical for HCC.
Sonography-guided liver biopsywas performed, which showed a
poorly differentiated carcinoma with extensive tumor necrosis
and scant residual hepatocytes. Necrotic tumor tissues were
dominant in the central area of the tumor, whereas viable tumor
cells were predominant over the peripheral regions. The tumor
comprised an epithelial component with somewhat trabecular
and/or glandular structures and focally sarcomatous differentia-
tion characterized by bizarre, spindle-shaped tumor cells (Fig. 3A
and B). Immunohistochemical studies demonstrated that these
tumor cells were immunoreactive to cytokeratin (CK) AE1/AE3
(Fig. 3C), CK7, and vimentin (Fig. 3D), but negative forHepar-1,
CD31, CD34, C-kit, CD68, smooth muscle actin, and S100.
Based on the radiologic features, histopathologic findings, and
immunohistochemical results, HCC with sarcomatous change
was diagnosed.
The patient refused surgical resection, radiofrequency abla-
tion (RFA), or transarterial chemoembolization (TACE) and
received target therapy with sorafenib and underwent outpatient
department follow-up. The patient was admitted to the hospital
several times because of refractory ascites, diarrhea, and
abdominal distention with frequent vomiting, due to disease
progression with carcinomatosis over the whole abdominal cav-
ity. The patient died in the hospital 3 months after diagnosis.of the liver with a complete cystic mass measuring 9.0  9.5  9.3 cm (white
l; and (D) delay phases demonstrated that the cystic mass showed no contrast
duct dilatation was seen.
Fig. 3. (A) Liver core needle biopsy showing a poorly differentiated carcinoma with focal spindle cell transformation. (B) Pleomorphic and hyperchromatic spindle
tumor cells (right and upper part) with prominent tumor necrosis (left and lower part); hematoxylin and eosin staining. (A) Original magnification 200 and (B)
400. Immunohistochemical examination revealed that sarcomatous elements were positive for (C) cytokeratin AE1/AE3 and (D) vimentin.
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We searched the PubMed database for case reports on
sarcomatous HCC published in English (articles published be-
tween 2001 and 2011 were searched) using the following key-
words: “sarcomatous” and “hepatocellular carcinoma”. The
inclusion criteria were availability of full text and papers withTable 1
Clinical findings of sarcomatous hepatocellular carcinoma in 14 patients.
Case Sex Age (y) AFP
(ng/mL)
Central
necrosis
Soft
tissue part
Liver
capsule rupture
1 Male 71 1.3 þ þ þ
2 Male 73 120.9 þ þ e
3 Male 56 3 þ þ e
4 Male 66 536 þ þ e
5 Male 63 848 þ þ þ
6 Male 72 WNL þ þ e
7 Male 79 3772 þ þ e
8 Male 53 323 e þ e
9 Male 66 4.7 þ þ e
10 Male 72 17.1 þ þ e
11 Male 74 WNL þ þ e
12 Male 70 WNL þ þ þ
13 Male 59 3 þ þ e
Present Male 49 1270 þ e þ
AFP ¼ alpha-fetoprotein; ND ¼ not described; TACE ¼ transarterial chemoembo
a Duration since diagnosis.CTor magnetic resonance imaging features. A total of 13 cases
were found.5e17 The clinical and image features of the 13 pre-
vious cases of sarcomatousHCC and our case are summarized in
Table 1. Central necrosis, which is the predominant CT feature
of sarcomatous HCC, was seen in 12 of the 13 tumors (92.3%);
among these cases, the present case showed a huge, homoge-
neous mass with complete central necrosis and rupture of theTreatment Complication Follow-upa Reference
Supportive Leukemoid reaction Dead (7 mo) 5
Surgical resection No recurrence Alive (19 mo) 6
Surgical resection with
liver transplantation
Local recurrence Dead (3 mo) 7
Surgical resection Hepatic failure Dead (3 mo) 8
Surgical reaction Local recurrence,
distal metastasis
Dead (8 mo) 9
Surgical resection No recurrence Alive (30 mo) 10
Surgical resection ND Alive (12 mo) 11
Surgical resection with
liver transplantation
Distal metastasis Dead (12 mo) 12
Surgical resection, TAE Local recurrence,
distal metastasis
Dead (4 mo) 13
Surgical resection ND ND 14
TACE Leukemoid reaction Dead (2 mo) 15
Surgical resection Distal metastasis Dead (1 mo) 16
Surgical resection,
chemotherapy
ND Alive (12 mo) 17
Target therapy Hepatic failure Dead (3 mo) d
lization; TAE ¼ transarterial embolization; WNL ¼ within normal limits.
268 Y. Hung et al. / Journal of the Chinese Medical Association 77 (2014) 265e268liver capsule and with no contrast enhancement or washout
lesion on three-phase dynamic contrast-enhanced CT. Thus, the
case presented here represents an extremely unusual CT pre-
sentation of sarcomatous HCC.
The prognosis is poor in patients with sarcomatous HCC, due
to its significantly higher frequency of recurrence or metastasis
compared with ordinary HCC.7 Most patients die within 1 year,
even after undergoing anticancer therapy such as chemotherapy
or radiotherapy. In the cases reviewed here, 11 patients under-
went surgery and four of these patients (36.3%) survived more
than 1 year. According to the American Association for the
Study of Liver Diseases (AASLD) practice guidelines,18 our
patient was classified as HCC, Barcelona Clinic Liver Cancer
(BCLC) Stage C and was not resectable. The patient refused to
undergo TACE and therefore sorafenib was administrated, a
multikinase inhibitor with activity against Raf-1, B-Raf,
vascular endothelial growth factor receptor 2, platelet-derived
growth factor receptor, and c-Kit receptors. Sorafenib is now
the first-line target therapeutic agent for patients with unre-
sectable HCC who are not suitable for RFA or TACE.
In conclusion, sarcomatous HCC is a rare variant of HCC,
and central necrosis is the most common CT feature of these
tumors. Patients with HCC should be evaluated first for sur-
gical resection. If the HCC is not resectable, other local
therapy (such as RFA) or TACE should be considered. Based
on the AASLD guidelines, for patients with advanced stage
(BCLC Stage C) HCC but Child classification A, like the case
presented here, the treatment of choice is the target therapy
with sorafenib. The patient died 3 months after sorafenib
treatment due to poor response. The poor outcome might have
been too late for the recognition of the HCC (liver capsule
rupture). Early recognition of the tumor and surgical resection
may have a better prognosis in some patients.
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